Discordance between central (Brain) and pancreatic action of exenatide in lean and obese subjects

Diabetes Care

Volumn 39, Issue 10, 2016, Pages 1804-1810

  Eldor, Roy ^a   Daniele, Giuseppe ^a   Huerta, Claudia ^a   Al Atrash, Mariam ^a   Adams, John ^a   De Fronzo, Ralph ^a   Duong, Timothy ^a   Lancaster, John ^a   Zirie, Mahmoud ^b   Jayyousi, Amin ^b   Abdul Ghani, Muhammad ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HAMAD GENERAL HOSPITAL   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; INSULIN; PEPTIDE; VENOM;

ADULT; AMYGDALA; ARTICLE; BRAIN FUNCTION; CALORIE; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; FEMALE; FOOD INTAKE; FOOD PICTURE; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCAGON RELEASE; GLUCOSE TOLERANCE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIC CLAMP TECHNIQUE; IMAGE DISPLAY; INFUSION; INSULA; INSULIN RELEASE; LEAN BODY WEIGHT; MALE; MIDDLE AGED; OBESITY; PANCREAS FUNCTION; REWARD; SALINE INFUSION; VISUAL STIMULATION; AGONISTS; BLOOD; BODY MASS; BRAIN; DIAGNOSTIC IMAGING; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; IMAGE PROCESSING; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; SECRETION (PROCESS);

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; BRAIN; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; IMAGE PROCESSING, COMPUTER-ASSISTED; INSULIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBESITY; PANCREAS; PEPTIDES; VENOMS;

EID: 84988958907     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2706     Document Type: Article

References (23)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-497
2. Reaven GM. Insulin resistance: The link between obesity and cardiovascular disease. Med Clin North Am 2011;95:875-892
3. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers 2015;1:15019
4. Hussain SS, Bloom SR. The regulation of food intake by the gut-brain axis: Implications for obesity. Int J Obes 2013;37:625-633
5. Tang DW, Fellows LK, Small DM, Dagher A. Food and drug cues activate similar brain regions: A meta-analysis of functional MRI studies. Physiol Behav 2012;106:317-324
6. Stoeckel LE, Weller RE, Cook EW 3rd, Twieg DB, Knowlton RC, Cox JE. Widespread rewardsystem activation in obese women in response to pictures of high-calorie foods. Neuroimage 2008;41:636-647
7. Murdaugh DL, Cox JE, Cook EW3rd,Weller RE. fMRI reactivity to high-calorie food pictures predicts short- and long-term outcome in a weight-loss program. Neuroimage 2012;59: 2709-2721
8. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
9. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagonlike peptide 1 on appetite and body weight: Focus on the CNS. J Endocrinol 2014;221:T1-T16
10. ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia 2015;58:2688-2698
11. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009;150:1680-1687
12. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-1791
13. Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009;52:199-207
14. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223
15. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanismof action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008;294:E846-E852
16. Daniele G, Iozzo P, Molina-Carrion M, et al. Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system. Diabetes 2015; 64:3406-3412
17. Lancaster JL, Tordesillas-GutiérrezD,Martinez M, et al. Bias between MNI and Talairach coordinates analyzed using the ICBM-152 brain template. Hum Brain Mapp 2007;28:1194-1205
18. Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for functional brainmapping. Hum Brain Mapp 2000;10:120-131
19. Lancaster JL, Rainey LH, Summerlin JL, et al. Automated labeling of the human brain: A preliminary report on the development and evaluation of a forward-transform method. Hum Brain Mapp 1997;5:238-242
20. van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 2014;63:4186-4196
21. van Bloemendaal L, Veltman DJ, Ten Kulve JS, et al. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. Diabetes Obes Metab 2015;17:878-886
22. Matsuda M, Liu Y, Mahankali S, et al. Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes 1999; 48:1801-1806
23. Rosenstock J, Shenouda SK, Bergenstal RM, et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012;35:955-958 South Texas Veterans Health Care System